Jump to content

All Activity

This stream auto-updates

  1. Past hour
  2. Putin has won free and fair for how long?
  3. that video is sickening, student understands that she'll have to interact with 'illegal' genders in the real world ?
  4. Good, I got shit to do too Worst loss of the season
  5. That’s what is so frustrating. That lineup they trotted out Saturday? There’s not a hole in it. Not everyone is great but there’s not a single below average hitter in it. we scored 11. First time we’d seen the lineup all year. We haven’t seen it since.
  6. We don't seem interested in playing October baseball.
  7. 11 hits 3 runs but still fuck you abreu
  8. https://www.threads.com/@marco.foster/post/DOYlMpBjuFp?xmt=AQF09XZOaBS76twaR_2CJgMkSey5q9gBlYdgBDiXx3kFKA&slof=1
  9. abbott has a plan and no one is going to stop it
  10. Re: IBRX, this release today. Positive phase 2 data in lung cancer, let's land a phase 3. ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy September 8, 2025 PDF Version Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lowers overall survival in non-small cell lung cancer and multiple types of cancer.1,2 With ANKTIVA, the first FDA-approved lymphocyte-stimulating agent, 80% of patients exceeded or maintained absolute lymphocyte count (ALC) above 1,000 cells/µL. With ALC counts greater than 1,500 cells/µL, statistically significant prolonged median overall survival (OS) of 21.1 months occurred with patients alive ranging as long as over 4 years in stark contrast to the historical 7 to 9 months survival with docetaxel in these patients with advanced lung cancer. Findings from the Phase 2 QUILT-3.055 study presented at IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain represent a paradigm change in a chemotherapy-free treatment of lung cancer by activating Natural Killer cells and T cells, the lymphocytes key to inducing cancer cell death. Patients are currently being enrolled in the randomized Phase 3 ResQ201A trial (NCT06745908), which is evaluating ANKTIVA + tislelizumab, a checkpoint inhibitor versus docetaxel alone in second-line NSCLC patients who have progressed after all standard therapies, including checkpoint inhibitors.
  11. Shut the fuck up with your CR commentary. Take it to the cesspool board where it belongs.
  12. Buncha fuckin 2%ers. But seriously, that's nice to know. I "hate" aggy, but it's really not fun actually hating aggy as represented by those troglodytes on Texas.
  13. Fuck this team for their cocktease in June and early July. Sucked us all in with their scrappy play. Just lipstick on a pig - an average at best team with an idiot for a manager and a roster full of holes. Watching this team the past 2 months has been torture. Fuck Crane and Dana for inflicting this shit on H-town.
  14. Brice time. We're not winning jack this year, so throw some fresh meat onto the grill. And just get the inevitable Espada canning over with.
  15. Well... Fuck.
  16. They’ve broken me. I no longer hate this team. I applaud what they are doing as a great piece of trolling and performance art. Bravo Astros, Bravo.
  17. Can’t afford to lose one like this.
  18. Lose the rest. Fire Espada
  1. Load more activity


×
×
  • Create New...